European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
Standard
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. / Engelhardt, Monika; Udi, Josefina; Kleber, Martina; Spencer, Andrew; Rocci, Alberto; Knop, Stefan; Bruno, Benedetto; Bringhen, Sara; Pérez-Simón, José A; Zweegman, Sonja; Driessen, Christoph; Patriarca, Francesca; Gramatzki, Martin; Terpos, Evangelos; Sezer, Orhan; Kropff, Martin; Straka, Christian; Johnsen, Hans E; Waage, Anders; Boegsted, Martin; Lokhorst, Henk; Hájek, Roman; Morgan, Gareth; Boccadoro, Mario; Ludwig, Heinz; Cavo, Michele; Polliack, Aaron; Sonneveld, Pieter; Einsele, Hermann; Palumbo, Antonio.
In: LEUKEMIA LYMPHOMA, Vol. 51, No. 11, 11, 2010, p. 2006-2011.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
AU - Engelhardt, Monika
AU - Udi, Josefina
AU - Kleber, Martina
AU - Spencer, Andrew
AU - Rocci, Alberto
AU - Knop, Stefan
AU - Bruno, Benedetto
AU - Bringhen, Sara
AU - Pérez-Simón, José A
AU - Zweegman, Sonja
AU - Driessen, Christoph
AU - Patriarca, Francesca
AU - Gramatzki, Martin
AU - Terpos, Evangelos
AU - Sezer, Orhan
AU - Kropff, Martin
AU - Straka, Christian
AU - Johnsen, Hans E
AU - Waage, Anders
AU - Boegsted, Martin
AU - Lokhorst, Henk
AU - Hájek, Roman
AU - Morgan, Gareth
AU - Boccadoro, Mario
AU - Ludwig, Heinz
AU - Cavo, Michele
AU - Polliack, Aaron
AU - Sonneveld, Pieter
AU - Einsele, Hermann
AU - Palumbo, Antonio
PY - 2010
Y1 - 2010
N2 - Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even better predictive potential. In order to achieve even more effective and individualized therapies, one crucial goal is the identification of genes and gene combinations that predict for response or resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM.
AB - Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even better predictive potential. In order to achieve even more effective and individualized therapies, one crucial goal is the identification of genes and gene combinations that predict for response or resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM.
KW - Humans
KW - Europe
KW - Research Design
KW - Clinical Trials as Topic methods
KW - Consensus Development Conferences as Topic
KW - Expert Testimony
KW - Information Services
KW - Multiple Myeloma therapy
KW - Salvage Therapy
KW - Humans
KW - Europe
KW - Research Design
KW - Clinical Trials as Topic methods
KW - Consensus Development Conferences as Topic
KW - Expert Testimony
KW - Information Services
KW - Multiple Myeloma therapy
KW - Salvage Therapy
M3 - SCORING: Zeitschriftenaufsatz
VL - 51
SP - 2006
EP - 2011
JO - LEUKEMIA LYMPHOMA
JF - LEUKEMIA LYMPHOMA
SN - 1042-8194
IS - 11
M1 - 11
ER -
